Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has launched a research program with the Psychedelic Drug DMT to see its effect on stroke victims.
Moreau talks more about that drug known as “The Spirit Molecule: and when they are hoping to start a clinical trial.